Clinical Chemistry 51: 479-480, 2005;
10.1373/clinchem.2004.047597
(Clinical Chemistry. 2005;51:479-480.)
© 2005 American Association for Clinical Chemistry, Inc.
The Clinical Chemist
David E. Bruns, Editor
(dbruns{at}clinchem.aacc.org)
New Members of the Board of Editors
We welcome the new members of the Editorial Board whose terms began January 1, 2005.
Klaus Jung, MD,
is currently head of the Research Division of the Department of Urology and Professor at the University Hospital Charité, Campus Mitte, Berlin, Germany. He received his MD from the University of Rostock, Germany, in 1968 and additionally trained in biochemistry there. He completed his postdoctoral training in pathological biochemistry and clinical chemistry at the University of Magdeburg and at the Humboldt University Berlin. In 1971, he joined the Department of Clinical Biochemistry at the University Hospital Charité and was supervisor of the Laboratory of Clinical Enzymology. After his postdoctoral lecturing qualification (habilitation) in pathobiochemistry and laboratory medicine in 1979, he had responsibilities for the Pathobiochemical Laboratory of the Department of Experimental Organ Transplantation and was afterward named head of that department.
He is certified in laboratory medicine and clinical chemistry in Germany and the European Union (EurClinChem). In 1985, he received the Leonor Michaelis Award of the GDR-Society for Clinical Chemistry and Laboratory Diagnostics. He has served on the advisory boards of the European Journal of Clinical Chemistry and Clinical Biochemistry (1990–1994).
Dr. Jung is the author/coauthor of more than 420 scientific articles and book chapters spanning fields from basic research on mitochondrial function, ischemia, and organ preservation to different aspects in clinical chemistry, including serum and urinary enzymes, lipoproteins, and glomerular and tubular markers of kidney injury and renal transplant dysfunction. He has edited two books on clinical enzymology. Dr. Jung’s current research interests are focused on molecular urooncology (prostate, urothelial, and renal cell carcinoma) and the development of new tumor markers in urology and their diagnostic evaluation. The research activities of his group are supported by Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, and various foundations.
David A. Morrow, MD, MPH,
is an Assistant Professor of Medicine at Harvard Medical School and an Associate Physician in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, Boston, MA. Dr. Morrow earned his MD from Harvard Medical School and a masters in public health with a concentration in clinical study design and interpretation from the Harvard School of Public Health. He completed both a residency in internal medicine and a fellowship in cardiovascular disease at the Brigham and Women’s Hospital in Boston, MA.
Dr. Morrow is an active investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group at Brigham and Women’s Hospital with a research focus on clinical evaluation of biomarkers in cardiovascular disease. He has been a major contributor to the development and expansion of the TIMI Study Group Biomarker Program. He sits on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers, for which he leads the clinical section on acute coronary syndromes. He also serves on the Program Committee of the Council on Clinical Cardiology of the American Heart Association and is on the Board of Editors for the journal Circulation. Dr. Morrow has more than 75 original scientific reports, reviews, editorials, book chapters, and electronic publications in his areas of expertise.
William L. Roberts, MD, PhD,
is Director of the Automated Core Laboratory at ARUP Laboratories, Salt Lake City, UT, and an associate professor of pathology at the University of Utah. Dr. Roberts received his BS degree in chemistry from The Ohio State University in 1982, a PhD in pharmacology in 1988, and an MD in 1990 from Case Western Reserve University. In 1995, he completed residency training in laboratory medicine at Yale University and is board-certified in both clinical pathology and chemical pathology. He was an assistant professor of pathology at the University of Mississippi Medical Center from 1995 to 1998 and has been at the University of Utah and ARUP Laboratories since 1998. His research interests have included developing and validating new clinical assays, evaluating assay performance characteristics, performing method-comparison studies for a variety of different assays, studying the effects of hemoglobin variants on glycohemoglobin assays, and examining interfering substances for a variety chemistry assays. He is the author of 80 publications. He has been a member of the AACC since 1992 and currently serves on the Continuing Medical Education Committee for the AACC.
Ian Young, MD, FRCP, FRCPath
is Professor of Medicine at Queen’s University Belfast and Consultant Chemical Pathologist to the Royal Group of Hospitals, Belfast, Northern Ireland, where he is also director of research and development. Dr. Young received a BSc in biochemistry from Queen’s University Belfast in 1982 and graduated in medicine in 1985. He was appointed to a personal chair in medical biochemistry at Queen’s University in 1998 before becoming Professor of Medicine in 2001. His major research interests are in the role of oxidative stress in disease, particularly in relation to nutritional antioxidants and lipoprotein oxidation, and he has published over 150 scientific papers in these areas. Professor Young is chairman of the Scientific Committee of the Association of Clinical Biochemists in the United Kingdom and is a member of the IFCC Scientific Division.
